YMAB Stock Cash Flow Statements

Y-mAbs Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Y-mAbs Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

cash flows from operating activities
net income	-3,240,000	-5,196,000	-6,790,000	-6,998,000	-9,249,000	-6,629,000	-988,000	-7,747,000	-6,302,000	-6,390,000	1,157,000	-27,526,000	-41,131,000	-28,068,000						-32,832,000	-40,393,000	-26,179,000		-23,922,000	-18,036,000	-15,934,000	-14,060,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	53,000	71,000	102,000	121,000	153,000	159,000	161,000	168,000	224,000	182,000	230,000	226,000	188,000	195,000		145,000	216,000	130,000		93,000	100,000	86,000		48,000	20,000	19,000	14,000
stock-based compensation	2,902,000	3,341,000	3,079,000	4,195,000	3,439,000	3,846,000	3,123,000	2,410,000	3,616,000	5,304,000	3,537,000	3,341,000	13,633,000	5,091,000		4,901,000	4,827,000	4,698,000		3,134,000	2,454,000	2,211,000		1,345,000	971,000	864,000	495,000
foreign currency transactions	-1,940,000	-812,000											1,422,000	311,000		238,000	78,000	435,000		4,000	-91,000	25,000		134,000	-62,000	51,000	-4,000
changes in assets and liabilities:
accounts receivable	2,000,000	1,948,000	-292,000	2,275,000	-1,603,000	1,866,000	-3,580,000	244,000	-416,000	-6,171,000	-3,280,000	-2,043,000	2,116,000	-1,612,000		1,253,000	-2,520,000	-5,997,000
inventories	-1,670,000	-724,000	2,343,000	-1,059,000	-50,000	-3,383,000	2,048,000	-1,926,000	3,758,000	-2,243,000	-460,000	552,000	-1,206,000	-76,000		-967,000	-2,815,000	-1,005,000
insurance recovery receivable related to legal settlement
other current assets	368,000	-30,000	-2,911,000	781,000	1,239,000	1,473,000	-2,654,000	1,269,000	-320,000	1,722,000	-3,279,000	1,699,000	-150,000	1,370,000		646,000	1,291,000	2,993,000		2,381,000	-1,201,000	759,000		1,627,000	-267,000	902,000	-940,000
inventories, long-term	-751,000	-700,000
other assets	72,000	-230,000	5,930,000	-4,906,000	-2,287,000	1,318,000	-3,077,000	2,835,000	-3,587,000	-2,983,000	-80,000	149,000	1,089,000	-3,668,000		42,000	40,000	-1,543,000		-11,000	24,000	-11,000		-74,000	-1,000	-56,000	1,000
accounts payable	4,877,000	-1,223,000	-3,659,000	-1,132,000	3,230,000	176,000	-660,000	-47,000	-1,378,000	-4,771,000	-1,090,000	2,432,000	-3,370,000	1,109,000		4,221,000	260,000	-2,829,000		495,000	-435,000	1,740,000		-1,984,000	3,149,000	-134,000	-439,000
accrued liabilities and other	-1,020,000	-3,356,000	3,189,000	863,000	1,569,000	-2,795,000	-1,519,000	1,051,000	-11,000	2,682,000	-5,275,000	-30,000	4,309,000	423,000		303,000	2,804,000	-146,000		2,591,000	3,200,000	-387,000		1,431,000	186,000	805,000	1,356,000
accrued legal settlement
net cash from operating activities	1,651,000	-6,911,000	-1,870,000	-10,665,000	298,000	-3,477,000	-8,036,000	-1,338,000	-4,734,000	-13,124,000	-8,661,000	-19,235,000	-23,100,000	-24,925,000		-18,076,000	-18,756,000	-31,861,000		-24,145,000	-27,635,000	-21,756,000		-21,395,000	-14,040,000	-13,483,000	-13,577,000
capex	0	-127,000	0	0	0	0	0	0	0	0	0	0	0	0		-71,000	-41,000	-400,000		-103,000	-2,000	-26,000		-617,000	-75,000	-126,000	-57,000
free cash flows	1,651,000	-7,038,000	-1,870,000	-10,665,000	298,000	-3,477,000	-8,036,000	-1,338,000	-4,734,000	-13,124,000	-8,661,000	-19,235,000	-23,100,000	-24,925,000		-18,147,000	-18,797,000	-32,261,000		-24,248,000	-27,637,000	-21,782,000		-22,012,000	-14,115,000	-13,609,000	-13,634,000
net cash from investing activities	0	-127,000																61,610,000		-2,713,000	-2,000	-26,000		-617,000	-75,000	-126,000	-57,000
purchase of property and equipment	0	-127,000														-71,000	-41,000	-400,000		-103,000	-2,000	-26,000		-617,000	-75,000	-126,000	-57,000
cash flows from financing activities
proceeds from exercised stock options	332,000	114,000	986,000	979,000	1,758,000	588,000					0	52,000	0	32,000		248,000	131,000	110,000		215,000	0	370,000
net cash from financing activities	332,000	114,000	986,000	979,000	1,758,000	588,000					0	52,000	0	32,000		248,000	131,000	107,835,000		215,000	0	370,000					-1,842,000
effect of exchange rates on cash and cash equivalents				2,000	1,000	1,000	2,000	0	14,000	-9,000	-103,000	44,000	41,000	53,000	52,000	42,000	-18,000	53,000	176,510								24,000
net decrease in cash and cash equivalents	1,983,000	-6,924,000	-888,000	-9,684,000	2,057,000	-2,888,000	-7,934,000	-1,338,000	-4,720,000	-13,133,000									75,776,498
cash and cash equivalents at the beginning of period	0	67,234,000	0	0	0	78,637,000	0	0	0	105,762,000	0	0	0	181,564,000		0	0	114,634,000
cash and cash equivalents at the end of period	1,983,000	60,310,000	-888,000	-9,684,000	2,057,000	75,749,000	-7,934,000	-1,338,000	-4,720,000	92,629,000	-8,764,000	-19,139,000	-23,059,000	156,724,000		-17,857,000	-18,684,000	252,271,000

supplemental disclosure of non-cash activities
right-of-use assets obtained in exchange for lease obligations			0	0			0				0													69,000	-1,488,000	2,320,000
property and equipment purchase in accrued liabilities and other
foreign currency and other transactions			2,443,000	-1,180,000	232,000	492,000				-456,000	-121,000
benefit from bad debt
cash flows from investing activities
supplemental disclosure of cash flow information
cash paid for income taxes
acquisition of treasury shares upon repayment of secured promissory note
foreign currency transactions and other transactions							-890,000
intangible assets acquisition in accrued liabilities
acquisition of treasury shares upon repayment of secured promissory note – refer to note 10							0	0			0
intangible assets acquisition in accrued milestones and royalty payments													0	1,500,000
gain from sale of priority review voucher																0	0	-62,010,000
acquisition of intangible assets
net proceeds from sale of priority review voucher																0	0	62,010,000
proceeds from issuance of common stock, net of issuance costs																0	0	107,725,000									-1,842,000
net increase / (decrease) in cash and cash equivalents											-8,764,000	-19,139,000	-23,059,000	-24,840,000	-34,166,000	-17,857,000	-18,684,000	137,637,000
intangible assets acquisition in accrued milestones
property and equipment purchases in accounts payable																		60,000						729,000	-65,000	88,000
cash from operating activities
cash from / (used in) investing activities
cash from financing activities
non-cash expense in connection with equity issuance to msk/mit																				0
non-cash expense in connection with equity issuance to inventors																				0
loans to inventors
net cash provided by/ (used in) investing activities																-71,000
net income /																	-22,937,000	33,413,000
cash from investing activities
effect of exchange rates on cash, cash equivalents and restricted cash																					-78,000	50,000	-34,000	41,000	3,000	13,000
net decrease in cash, cash equivalents and restricted cash																					-27,715,000	-21,362,000
cash, cash equivalents and restricted cash at the beginning of period																					0	207,136,000		0	0	147,871,000	0
cash, cash equivalents and restricted cash at the end of period																					-27,715,000	185,774,000		-21,971,000	-14,112,000	134,275,000	-15,452,000
net increase in cash, cash equivalents and restricted cash																									-14,112,000	-13,596,000
payment of offering costs for private placement
net increase/(decrease) in cash, cash equivalents and restricted cash
common stock issuance costs in accounts payable
deferred offering costs included in other assets and accounts payable and accrued liabilities and other
payment of offering costs
net increase in cash and cash equivalents																											-15,452,000
supplemental disclosure of noncash financing activities
common stock issuance cost in accounts payable

We provide you with 20 years of cash flow statements for Y-mAbs Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Y-mAbs Therapeutics stock. Explore the full financial landscape of Y-mAbs Therapeutics stock with our expertly curated income statements.

The information provided in this report about Y-mAbs Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.